NovoCure Limited (NVCR)
NASDAQ: NVCR · Real-Time Price · USD
18.09
-0.37 (-2.00%)
Jul 11, 2025, 10:09 AM - Market open
Company Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally.
The company’s TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.
NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
NovoCure Limited
| Country | Switzerland |
| Founded | 2000 |
| IPO Date | Oct 2, 2015 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 1,488 |
| CEO | Ashley Cordova |
Contact Details
Address: Neuhofstrasse 21 Baar, 6340 Switzerland | |
| Website | novocure.com |
Stock Details
| Ticker Symbol | NVCR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001645113 |
| CUSIP Number | G6674U108 |
| ISIN Number | JE00BYSS4X48 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Ashley Cordova | Chief Executive Officer and Director |
| William F. Doyle | Executive Chairman |
| Barak Ben-Arye | General Counsel |
| Dr. Uri Weinberg M.D., Ph.D. | Chief Innovation Officer |
| Frank Leonard | Executive Vice President and President of Novocure Oncology |
| Christoph Brackmann | Chief Financial Officer |
| Mukund Paravasthu | Chief Operating Officer |
| Ingrid Goldberg | Vice President of Investor Relations |
| Michael Puri | Chief Human Resources Officer |
| Dr. Nicolas Leupin M.B.A., M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 7, 2025 | SCHEDULE 13G/A | Filing |
| Jun 30, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jun 30, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jun 30, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jun 30, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jun 30, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jun 30, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jun 30, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jun 6, 2025 | 8-K | Current Report |
| Jun 2, 2025 | 144 | Filing |